IA
CRSP icon

Inspire Advisors’s CRISPR Therapeutics CRSP Stock Holding History

Inspire Advisors’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.08M Buy
19,880
+116
+0.6% +$6.11K 0.08% 212
2026
Q1 		$940K Buy
19,764
+3,392
+21% +$179K 0.08% 206
2025
Q4 		$859K Buy
16,372
+2,513
+18% +$151K 0.08% 182
2025
Q3 		$898K Sell
13,859
-615
-4% -$35.3K 0.09% 182
2025
Q2 		$704K Buy
14,474
+999
+7% +$38.7K 0.07% 217
2025
Q1 		$459K Buy
+13,475
New +$571K 0.05% 278

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Inspire Advisors's CRSP Position: Q2 2026 in Review

Inspire Advisors increased its CRISPR Therapeutics (CRSP) stake by 0.59% in Q2 2026, buying an estimated $6.11K and bringing the position to 19,880 shares worth $1.08M. The position accounts for 0.08% of the portfolio, ranked #212.

Inspire Advisors first reported a position in CRSP in Q1 2025 and has held it in 6 quarters since. 524 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Inspire Advisors held 19,880 shares of CRISPR Therapeutics worth $1.08M as of Q2 2026.
  • Inspire Advisors bought 116 CRISPR Therapeutics shares in Q2 2026, an estimated $6.11K.
  • CRISPR Therapeutics made up 0.08% of Inspire Advisors's portfolio in Q2 2026, its #212 holding.
  • Inspire Advisors first reported a position in CRISPR Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • 524 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Inspire Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.